Neurocognitive Correlates of Behavioral Treatment for Childhood Tic Disorders
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 9 - 14 |
| Updated: | 4/21/2016 |
| Start Date: | July 2007 |
| End Date: | December 2011 |
TRECC: Neurocognitive Correlates of Behavioral Treatment for Childhood Tic Disorders
The study aims to clarify the functional anatomy of key brain circuits associated with
cognitive control in children and adolescents with chronic tic disorders (CTD) and to
compare and contrast hypothesized mechanisms related to increased tic control associated
with Habit Reversal Training, a behavioral treatment that been previously shown to be
effective in treating CTD. We also seek to better understand the relationship between fMRI
and quantitative EEG in relevant brain circuits with the hope of establishing EEG as a valid
and cost-effective marker of treatment responsiveness. A total of 25 subjects will be
randomized to 10 weeks of Habit Reversal Training (HRT), a behavioral treatment, and 25 to
10 weeks of minimal-contact waitlist. Treatment responders will be re-assessed at three
months. Waitlist nonresponders will be provided with 10 weeks of HRT. Study assessments,
including a neurocognitive battery and quantitative EEG will be administered at baseline, Wk
5, Wk 10, and 3-month follow-up. Neuroimaging (fMRI) will be conducted at baseline and Wk
10.
cognitive control in children and adolescents with chronic tic disorders (CTD) and to
compare and contrast hypothesized mechanisms related to increased tic control associated
with Habit Reversal Training, a behavioral treatment that been previously shown to be
effective in treating CTD. We also seek to better understand the relationship between fMRI
and quantitative EEG in relevant brain circuits with the hope of establishing EEG as a valid
and cost-effective marker of treatment responsiveness. A total of 25 subjects will be
randomized to 10 weeks of Habit Reversal Training (HRT), a behavioral treatment, and 25 to
10 weeks of minimal-contact waitlist. Treatment responders will be re-assessed at three
months. Waitlist nonresponders will be provided with 10 weeks of HRT. Study assessments,
including a neurocognitive battery and quantitative EEG will be administered at baseline, Wk
5, Wk 10, and 3-month follow-up. Neuroimaging (fMRI) will be conducted at baseline and Wk
10.
Inclusion Criteria:
- DSM-IV diagnostic criteria for CTD (CMVT or TS)
- Clinical Global Impressions - Severity Score > 3 (moderately ill or worse)
- YGTSS Total Score > 14 (or Total Score > 10 if CTD with motor tics only)
- Unmedicated or on stable psychotropic medication for at least 6 weeks prior to study
entry, with no planned changes for duration of study participation
- Child is fluent English speaker
- Parental Informed Consent and Child Informed Assent.
Exclusion Criteria:
- Total YGTSS Score>35 (Cases above this threshold otherwise eligible will be reviewed
by Clinical Caseness Panel for potential study participation)
- IQ < 80 on the Wechsler Abbreviated Scale of Intelligence (WASI)
- Problematic Substance Use or DSM-IV Conduct Disorder in past 3 months
- Lifetime DSM-IV diagnosis of PDD, Mania, or Psychotic Disorder
- Any serious psychiatric, psychosocial, or neurological condition requiring immediate
treatment other than that provided in the current study
- Previous treatment with four or more sessions of HRT for tics
- Contraindication to fMRI scan
We found this trial at
1
site
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
Click here to add this to my saved trials
